202 related articles for article (PubMed ID: 33402059)
1. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
2. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
3. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
[TBL] [Abstract][Full Text] [Related]
4. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V
Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602
[TBL] [Abstract][Full Text] [Related]
5. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
6. AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.
Lu J; Hu S; Wang W; Li J; Dong Z; Zhou J; Hai X
Toxicol Sci; 2018 Nov; 166(1):219-227. PubMed ID: 30376134
[TBL] [Abstract][Full Text] [Related]
7. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
Glass JL; Derkach A; Hilden P; King A; Seo SK; Ahr K; Kishtagari A; Levine RL; Tallman MS; Douer D
Leuk Res; 2021 Jul; 106():106569. PubMed ID: 33857746
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
10. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
11. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide in pediatric cancer - a case series and review of literature.
Abele M; Müller SL; Schleicher S; Hartmann U; Döring M; Queudeville M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2021 Aug; 38(5):471-485. PubMed ID: 33635158
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
14. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
Chen X; Fan S; Zhao Y; Zhou J
Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
[TBL] [Abstract][Full Text] [Related]
15. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D
Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459
[TBL] [Abstract][Full Text] [Related]
16. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
17. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.
Sugiura H; Nishimori H; Matsuoka H; Nakamura K; Fujii K; Fujii N; Matsuoka KI; Maeda Y
Acta Med Okayama; 2021 Apr; 75(2):219-224. PubMed ID: 33953429
[TBL] [Abstract][Full Text] [Related]
19. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
